Articles tagged with Cancer Medication
Researchers have developed a DNA sensor system to measure Topo II enzyme activity, which is crucial for anti-cancer therapy. The system achieved synchronous detection of both Topo II and Topo I in human cell extracts, providing new insights into cancer treatment.
Nutlin-3 targets p53-Mdm2 interaction, enhancing cancer cell growth arrest and apoptosis while producing minimal toxicity. Its potential as an alternative NPC therapy is explored in ongoing clinical trials.
Researchers at The Institute of Cancer Research found a genetic weakness, BTK addiction, that makes oesophageal cancer cells sensitive to ibrutinib. This discovery could lead to a new approach to treatment for oesophageal cancer patients with MYC mutations.
Researchers develop model using zebrafish larvae to predict personalized treatment of cancer, offering faster and safer option than current methods. The study confirms that zebrafish and mice react similarly to treatments, enabling timely answers in under two weeks.
A new study found that annual screening starting at age 40 reduces breast cancer-specific deaths by nearly 40%, compared to 23-31% reductions with other recommendations. The findings suggest that women starting annual mammography at age 40 may benefit from a significant reduction in breast cancer-related deaths.
Researchers at Duke University Medical Center have discovered a molecule, Takinib, that appears to spur cell death in tumors and inflammation. By targeting the TNF-alpha signaling process, Takinib inhibits an enzyme called TAK-1, which controls cell survival.
A study by Queen Mary University of London found that MS drug cladribine improves patients' mobility and self-care, in addition to reducing relapses. The benefits were significant enough for the European Medicines Agency to adopt a positive opinion on licensing the oral preparation.
Researchers discovered that combining a novel drug MI-773 with traditional chemotherapy cisplatin destroyed salivary gland tumor cells and prevented recurrence within 300 days. This combination therapy showed promise in treating adenoid cystic carcinoma, a rare cancer affecting 3,000-4,000 people annually.
Researchers at Dana-Farber Cancer Institute discover that CDK4/6 inhibitors not only halt cancer cell division but also spur the immune system to attack and kill cancer cells. The findings suggest that combining these drugs with immunotherapies may lead to greater anti-cancer effects.
Researchers found that formaldehyde, a toxin, is also used to fuel the one-carbon cycle in cells, producing DNA and amino acids. This discovery could lead to new cancer therapies by targeting this pathway.
A new study by Georgia Institute of Technology researchers has found that a widespread biological concept affecting cancer research could be incorrect up to two-thirds of the time. The study's findings suggest that targeting proteins based on messenger RNA levels may not be optimal, potentially leading to drug targeting errors.
The school has awarded over $3.5 million in grants since its opening in 2014, with the latest grant targeting breast cancer treatment. Dr. Kamaljit Kaur's research aims to develop peptides that target specific receptors on cancer cells, reducing toxic side effects and improving patient survival.
A recent study predicts cancer drug resistance and sensitivity by analyzing genomic alterations and their interactions. Researchers used The Cancer Genome Atlas dataset to create a map of oncogenic dependencies, revealing that certain genetic changes can make tumors resistant to some drugs while making them sensitive to others.
A Yale-led team has identified specific gene combinations that cause deadly brain cancer glioblastoma and found two mutations that make tumors resistant to chemotherapy. The new technology can also pinpoint triggers of other types of cancers.
Researchers found that patients with deeper tumor shrinkage due to targeted treatment had better progression-free survival and overall survival rates. The study suggests that initial response could be an early indicator of a drug's effectiveness, influencing both clinical trials and treatment goals.
Researchers at Mayo Clinic have identified a link between SPOP gene mutations and treatment resistance in prostate cancer. The discovery suggests ways to improve therapy by using these mutations as biomarkers. This breakthrough could lead to more effective treatments for this common and deadly form of cancer.
Researchers from Yale University studied 840 patients with curable cancers and found that those who used only alternative therapy had a higher risk of death. The study suggests that conventional cancer treatment is more effective in improving survival rates.
Researchers at the University of Missouri found that women with increased cadmium levels have a higher risk of endometrial cancer, with rates increasing by 22% in individuals with elevated levels. The study recommends limiting cadmium intake through diet and lifestyle changes to reduce associated cancer risks.
A new hybrid biomaterial delivers a chemotherapeutic agent and RNA interfering technology to silence drug resistance, resulting in substantial decrease in cancer cell viability. The material's ease of modification allows for swapping out components to suit specific cell lines and drugs.
Researchers at the University of Bradford have discovered a new drug candidate, HXR9, that targets HOX genes to prevent cancer cell growth and induce apoptosis. Combining HXR9 with another drug shows enhanced results in reducing cancer growth.
Researchers discovered gold nanoparticles can boost lung cancer treatment effects and reduce side effects by precisely targeting diseased cells. A tiny device containing these particles could potentially be used in humans to activate chemotherapy directly in tumors.
Researchers mapped an acquired mutation altering DNA make-up in 50% of patient tumor samples, identifying a new target for therapy. The discovery highlights the power of mutations to influence epigenetics in cancer cells.
A Tel Aviv University study finds that pre- and post-surgery administration of beta blockers and anti-inflammatory medication significantly reduces metastatic cancer recurrence. The treatment improves long-term survival rates and is safe, inexpensive, and easily administered.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
Researchers at King Abdullah University of Science & Technology have identified three traditional Saudi plants with potent anticancer substances, including topoisomerase inhibitors. The study suggests these compounds could be used to develop novel cancer treatments, but more research is needed before they can be tested in humans.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have published a study on K-80003, an anti-cancer agent that prevents activation of the PI3K pathway, resulting in inhibition of cancer cell growth.
Researchers at the University of Sheffield have discovered that methotrexate, an arthritis drug, shows promise in treating Polycythemia Vera, a type of blood cancer affecting 3,000 people annually. The treatment has been shown to suppress JAK/STAT pathway activation and normalise blood counts in mice models.
Research funded by Cancer Research UK identified NOX4 as a common mechanism responsible for cancer-associated fibroblasts (CAFs) formation in tumours. Targeting this enzyme could lead to new treatments and improve existing therapies.
Researchers have developed a new class of anti-cancer agents targeting cancer cells' 'Achilles' heel', improving outcomes for aggressive triple negative and HER2-positive breast cancers. The treatment, S63845, was found to be highly effective when combined with standard therapies.
A study published in The Oncologist found that cancer patients with delirium who visit emergency departments are more likely to be admitted to hospital and die earlier. Delirium can be caused by various factors, including advanced cancer itself, medications, or infections.
A study by the Lung Cancer Mutation Consortium identified HER2 mutations in 24 lung cancer patients (3%), with median survival doubling when treated with HER2-directed therapy. This finding suggests a significant population of HER2+ lung cancer patients, highlighting the need for targeted therapies.
Researchers found an increased mutation rate in genes, including TP53, among African-American patients with smoking-related cancers. The study suggests that these genetic differences may contribute to resistance to chemotherapy and poorer outcomes.
The NRG-RTOG 0436 trial found that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer. The trial showed no significant benefit from the addition of EGFR inhibitor cetuximab to standard treatment.
Researchers identified a cellular signaling pathway blocking immune cell infiltration into bladder tumors, explaining the limited success of checkpoint immunotherapy. The finding suggests targeting this pathway could enhance treatment effectiveness when combined with checkpoint immunotherapy.
A new method developed by an international research team uses yeast cells to speed up drug discovery by linking compounds to cellular processes they target. The study found that natural compounds derived from soil microbes hold promise as potential medicines against various diseases, including infections and cancer.
The first Lancet Commission on Dementia Prevention and Care identifies powerful tools to prevent dementia. Nonmedical interventions such as social contact and exercise can reduce the incidence of dementia by up to 20% in early life and 15% in late life, according to a new report.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a novel synthetic lethality screen to discover molecules that target genetically modified yeast lacking NF1. The team identified one lead candidate called Y100, which disrupts tumor cell growth and induces oxidative stress causing death of NF1-deficient cancer cells.
Researchers at University of California San Diego School of Medicine have been awarded a $5.8 million CIRM grant to develop an immunotherapy that targets cancer stem cells using CAR T-cell therapy. The treatment aims to improve the ability of immune cells to target and kill multiple types of cancers.
A molecular analysis of tissue mismatch between donors and recipients predicted which recipients needed high doses of immune modulating drugs. The study found a strong correlation between low medication levels and low molecular mismatch scores, allowing physicians to tailor treatment to individual patients.
A new screening method using CRISPR-Cas9 genome editing technology has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapy. The study identified Ptpn2 as a key gene that makes tumor cells more susceptible to PD-1 blockade.
Researchers at the GW Cancer Center discovered that removing the HDAC11 enzyme from T-cells enhances their ability to attack cancer tumors. The study highlights this enzyme as a key regulator of T-cell function and a potential target for immunotherapy.
A Massachusetts General Hospital research team found that anti-angiogenic drugs induce a microenvironment that suppresses immune systems actions, allowing tumors to grow. Developing a potential strategy to overcome this mechanism, the researchers identified CX3CL1 as an attractive target for immunotherapy.
The cyclin-dependent kinase (CDK) inhibitor class of oral drugs has been found to be generally well-tolerated in treating hormone receptor-positive (HR+) metastatic breast cancer. The most common side effect is a temporary and dose-dependent decrease in white blood cells, which usually returns to normal with dosage adjustments.
Researchers at UCSF developed a computational method to analyze open-access data and identify new treatments for cancer. The method, called Reverse Gene Expression Score (RGES), predicts drug efficacy by analyzing molecular characteristics of real tumors. Four drugs were identified with potential to treat liver cancer and other diseases.
A preclinical study published in PNAS found that BMTP-11 targets high-risk osteosarcoma and shows anti-tumor activity. The treatment has the potential to reduce cumulative side effects associated with current treatments, which often cause health problems and organ damage.
Researchers at the University of Liverpool have developed a novel approach to treating chronic myeloid leukemia (CML), which safely increases treatment success and reduces negative side effects. The study, led by Professor Richard Clark, shows that CML patients with stable responses to treatment can reduce their medication dosage befor...
TAK228 enhances radiation and chemotherapy for diffuse intrinsic pontine glioma (DIPG) and atypical teratoid/rhabdoid tumors (AT/RT), two childhood brain cancers with poor prognosis. The drug reduces tumor cell proliferation and increases cancer cell death, particularly when combined with treatment.
Three case reports published in NEJM demonstrate the efficacy of cancer immunotherapy in gray zone lymphoma, a rare subtype of Hodgkin and Non-Hodgkin forms of the disease. Nivolumab and pembrolizomab showed promising results in treating patients with PD-L1 over-expression.
Researchers at CNIO found that Plk1 inhibitors can cause hypertension and severe cardiovascular problems, suggesting a need for more thorough studies on protein functions. The study used laboratory mice to model human diseases, revealing the critical role of Plk1 in maintaining blood pressure.
A recent study published in Annals of Internal Medicine found that moderate to heavy coffee consumption was linked to a lower risk of death from various causes. The research, which analyzed data from over 215,000 participants, suggests that the association is not tied to caffeine.
Researchers found that SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HPV-negative head and neck squamous cell carcinoma (HNSCC) patients. The study suggests that targeting pro-survival pathways may be a novel strategy for overcoming cetuximab resistance.
A new nurse-led intervention helps carers manage medication and cancer pain, offering a systematic and comprehensive approach to supporting carer management of pain medicines. The intervention promotes self-evaluation of competence and addresses carers' beliefs, knowledge, and skills.
Women who receive false-positive mammogram results are more likely to begin medication for anxiety or depression than those with immediate negative results. A 10-20% higher rate of prescription medications was found in patients requiring multiple tests to rule out a breast cancer diagnosis.
A personal neoantigen vaccine has been shown to stimulate a potent, safe, and highly specific immune response in melanoma patients. The vaccine targets distinctive 'neoantigens' on tumor cells, inducing a focused T cell response against several tumor neoantigens.
Researchers have developed a method to visualize cancer metastasis in whole organs at the single-cell level, enabling early detection of dormant or resistant cancer cells. This breakthrough uses transparent mice and advanced imaging techniques to create 3-D maps of cancer cells throughout the body and organs.
A consortium of researchers has performed a comprehensive genomic sequencing analysis of hundreds of patients with T-lineage acute lymphoblastic leukemia, revealing new mutations and drug targets. The study identified 106 driver genes associated with cancer, including previously unrecognized mutations.
The University of Texas at Arlington has awarded three new seed grants for interdisciplinary research projects addressing skin cancer, rapid drug evaluation and mental health risks among homeless youth. The projects aim to develop innovative treatments and programs using cutting-edge technology.
Research found that genes responsible for differential RNA splicing contribute to tumor aggressiveness and drug resistance in African American men with prostate cancer. The study suggests these genetic variations lead to the production of protein isoforms that make tumors more aggressive, while also causing drug resistance.
Nicole F. Steinmetz receives two NIH grants to develop microscopic drug-delivery systems for triple negative breast cancer patients and patients at risk of serious blood clots. The funding will enable her team to explore mechanisms behind anti-tumor effects and develop dual-pronged therapeutic approaches.
The National Cancer Institute's Proteogenomic Translational Research Centers aim to bring proteogenomics to cancer patients. By analyzing blood samples, researchers hope to identify proteins that indicate response to specific treatments.